Please login to the form below

Not currently logged in
Email:
Password:

Duodopa

This page shows the latest Duodopa news and features for those working in and with pharma, biotech and healthcare.

SMC approves Amgen orphan drug for use in NHS Scotland

SMC approves Amgen orphan drug for use in NHS Scotland

Also accepts AbbVie's former orphan drug Duodopa, but rejects Sanofi's Jevtana.  . ... The health technology assessment body also approved AbbVie's drug/device combination Duodopa (co-careldopa) for advanced Parkinson's disease.

Latest news

  • AbbVie sales jump on strong Humira gains AbbVie sales jump on strong Humira gains

    and Duodopa. ... Non-US sales of drug-device combination Duodopa for Parkinson's disease grew around 25 per cent to $44m, and AbbVie said it remains hopeful of approval for the product in

  • Chasing the cure for Parkinson's disease Chasing the cure for Parkinson's disease

    AbbVie (formerly Abbott Laboratories) is developing an intraduodenal gel formulation of levodopa/carbidopa (LGIC; Duodopa) for the treatment of late-stage Parkinson's in patients who have failed conventional oral levodopa

  • R&D news in brief

    ìSLV308 is for less advanced stages of Parkinson's disease, while the recently acquired drug Duodopa is intended for people suffering from late-stages of the disease so there are good

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics